Dr. Schadendorf Discusses Sequencing Agents in Melanoma

Dirk Schadendorf, MD
Published: Wednesday, Dec 20, 2017



Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses sequencing agents in melanoma.

Schadendorf says that it is currently unclear whether administering combination therapy upfront or beginning with targeted therapy and maintaining response by using a checkpoint blockade is more beneficial. There are ongoing clinical trials evaluating these strategies, but there is a waiting period.


Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses sequencing agents in melanoma.

Schadendorf says that it is currently unclear whether administering combination therapy upfront or beginning with targeted therapy and maintaining response by using a checkpoint blockade is more beneficial. There are ongoing clinical trials evaluating these strategies, but there is a waiting period.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x